Back to all bills
S 483119th CongressIntroduced
Responsibility in Drug Advertising Act of 2025
Introduced: Oct 29, 2025
Standard Summary
Comprehensive overview in 1-2 paragraphs
The Responsibility in Drug Advertising Act of 2025 restricts direct-to-consumer drug advertising by imposing a 3-year ban after FDA approval, with possible waivers, and allows continued restrictions for drugs with significant adverse health effects.
Key Points
- 1Imposes a 3-year prohibition on direct-to-consumer advertising for newly approved drugs
- 2Allows Secretary of Health and Human Services to grant waivers during the third year for drugs with affirmative public health value
- 3Permits continued restrictions beyond 3 years for drugs with significant adverse health effects based on post-approval data
- 4Applies to advertising on social media platforms and traditional media
- 5Establishes enforcement mechanisms through the Federal Food, Drug, and Cosmetic Act
- 6Effective for drugs approved on or after one year before enactment
Impact Areas
Pharmaceutical companies and drug manufacturersConsumers and patientsHealthcare providersSocial media platformsFederal Trade Commission and FDAPublic health
Generated by kwaipilot/kat-coder-pro:free on Nov 19, 2025